In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
In China, For Global
An innovative and globally competitive
biopharmaceutical company with a whole-industry-chain layout.
Original Innovation, Science Oriented
Globally-integrated R&D process
Technology system encompassing the entire lifecycle of antibodies
Innovation-driven Biopharma
China’s leading innovative biopharmaceutical company
Established in December, 2012
Therapeutic Area
Oncology
Toripalimab (PD-1), Tifcemalimab (BTLA)…
Autoimmune
Adalimumab (TNF-α), JS005 (IL-17A), UBP1213sc (BLyS)
Metabolic
Ongericimab (PCSK9), JS103 (Uricase), JS401 (ANGPTL3)…
Neurological
Infectious
Etesevimab (S protein), Deuremidevir Hydrobromide (RdRp)…
Therapeutic Area
Oncology
Autoimmune
Metabolic
Neurological
Infectious
Learn more
2012.12
Junshi Biosciences was established in Shanghai, the PRC.
2018.12
Toripalimab（TUOYI® , JS001）was granted marketing approval by the NMPA.
2023.10
Toripalimab（LOQTORZI™）was granted marketing approval by the FDA.
Learn more
News Center
May 27, 2025
Junshi Biosciences Announces Ongericimab’s sNDA Approval in China
>The NMPA has recently approved ongericimab's two sNDA, becoming China’s first domestic PCSK9-targeted drug approved for statin-intolerant patients
View details
Apr 25, 2025
Junshi Biosciences Announces the sNDA Approval of Toripalimab for the 1st-line Treatment of Melanoma
>This marks the approval of toripalimab’s 12th indication in the Chinese mainland.
View details
Mar 26, 2025
Junshi Biosciences Announces Toripalimab’s Approval in Singapore
>SHANGHAI, China, March 26, 2025 — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the New Drug Application (the “NDA”) for toripalimab (Singapore trade name: LOQTORZI®) in combination with cisplatin and gemcitabine for the first-line […]
View details
Nov 16, 2024
Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab
>The UK MHRA has approved toripalimab for the treatment of NPC and ESCC
View details
